| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
|
Brown, E.R.
|
|
|
19 |
7 |
p. 1340-1346
|
article
|
| 2 |
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
|
Borner, M.
|
|
|
19 |
7 |
p. 1288-1292
|
article
|
| 3 |
Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease
|
Prasad, K.N.
|
|
|
19 |
7 |
p. 1299-1303
|
article
|
| 4 |
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)
|
Theodore, C.
|
|
|
19 |
7 |
p. 1304-1307
|
article
|
| 5 |
Breast lymphoma
|
Avilés, A.
|
|
|
19 |
7 |
p. 1360
|
article
|
| 6 |
Cancer survivorship: a challenge for the European oncologists
|
Simonelli, C.
|
|
|
19 |
7 |
p. 1216-1217
|
article
|
| 7 |
Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma
|
Troch, M.
|
|
|
19 |
7 |
p. 1336-1339
|
article
|
| 8 |
Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
|
Mantovani, G.
|
|
|
19 |
7 |
p. 1355
|
article
|
| 9 |
Coincidential successful treatment of Jessner–Kanof disease with chemotherapy
|
Ardavanis, A.
|
|
|
19 |
7 |
p. 1360-1361
|
article
|
| 10 |
Comment on: ‘Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome’
|
Errante, D.
|
|
|
19 |
7 |
p. 1359-1360
|
article
|
| 11 |
Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer
|
Mahner, S.
|
|
|
19 |
7 |
p. 1249-1254
|
article
|
| 12 |
Defining prognosis for women with breast cancer and CNS metastases by HER2 status
|
Dawood, S.
|
|
|
19 |
7 |
p. 1242-1248
|
article
|
| 13 |
Disambiguating the bisphosphonates
|
Van den Wyngaert, T.
|
|
|
19 |
7 |
p. 1357-1359
|
article
|
| 14 |
Editorial Board
|
|
|
|
19 |
7 |
p. ii-iii
|
article
|
| 15 |
Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression
|
Psyrri, A.
|
|
|
19 |
7 |
p. 1271-1277
|
article
|
| 16 |
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
|
Arcaini, L.
|
|
|
19 |
7 |
p. 1331-1335
|
article
|
| 17 |
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients
|
Braconi, C.
|
|
|
19 |
7 |
p. 1293-1298
|
article
|
| 18 |
Insulin receptor substrate protein 53 (IRSp53) as a binding partner of antimetastasis molecule NESH, a member of Abelson interactor protein family
|
Matsuda, S.
|
|
|
19 |
7 |
p. 1356-1357
|
article
|
| 19 |
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
|
Martin, P.
|
|
|
19 |
7 |
p. 1327-1330
|
article
|
| 20 |
In this issue
|
|
|
|
19 |
7 |
p. 1211
|
article
|
| 21 |
Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?
|
Suzuki, S.
|
|
|
19 |
7 |
p. 1284-1287
|
article
|
| 22 |
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
|
Sirohi, B.
|
|
|
19 |
7 |
p. 1312-1319
|
article
|
| 23 |
Pancreatic cancer—is the wall crumbling?
|
Chua, Y.J.
|
|
|
19 |
7 |
p. 1224-1230
|
article
|
| 24 |
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy
|
Diéras, V.
|
|
|
19 |
7 |
p. 1255-1260
|
article
|
| 25 |
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
|
Regan, M.M.
|
|
|
19 |
7 |
p. 1231-1241
|
article
|
| 26 |
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
|
Bidard, F.-C.
|
|
|
19 |
7 |
p. 1261-1265
|
article
|
| 27 |
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study
|
von Moos, R.
|
|
|
19 |
7 |
p. 1266-1270
|
article
|
| 28 |
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias
|
Capdeville, R.
|
|
|
19 |
7 |
p. 1320-1326
|
article
|
| 29 |
Response of malignant thymoma to erlotinib
|
Christodoulou, C.
|
|
|
19 |
7 |
p. 1361-1362
|
article
|
| 30 |
Src as a potential therapeutic target in non-small-cell lung cancer
|
Giaccone, G.
|
|
|
19 |
7 |
p. 1219-1223
|
article
|
| 31 |
Stopping a trial early in oncology: for patients or for industry?
|
Trotta, F.
|
|
|
19 |
7 |
p. 1347-1353
|
article
|
| 32 |
Table of Contents
|
|
|
|
19 |
7 |
p. iv-v
|
article
|
| 33 |
The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients
|
Del Mastro, L.
|
|
|
19 |
7 |
p. 1213-1215
|
article
|
| 34 |
The postchemotherapy PSA surge syndrome
|
Thuret, R.
|
|
|
19 |
7 |
p. 1308-1311
|
article
|
| 35 |
The role of DNA ploidy in postoperative management of stage I endometrial cancer
|
Mangili, G.
|
|
|
19 |
7 |
p. 1278-1283
|
article
|
| 36 |
Volume 18, Supplement 3, A global comparison regarding patient access to cancer drugs
|
|
|
|
19 |
7 |
p. 1363
|
article
|
Journal description